LZIC

Summary

LZIC (leucine zipper and CTNNBIP1 domain containing, HGNC:17497) is a protein-coding gene on chromosome 1p36.22, encoding Protein LZIC (Q8WZA0).

Predicted to enable beta-catenin binding activity.

Source: NCBI Gene 84328 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 29 total
• Druggable target: yes
• MANE Select transcript: NM_032368

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17497
Approved symbol	LZIC
Name	leucine zipper and CTNNBIP1 domain containing
Location	1p36.22
Locus type	gene with protein product
Status	Approved
Aliases	MGC15436
Ensembl gene	ENSG00000162441
Ensembl biotype	protein_coding
OMIM	610458
Entrez	84328

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 17 protein_coding, 1 retained_intron

ENST00000377213, ENST00000377223, ENST00000400903, ENST00000471853, ENST00000488540, ENST00000867510, ENST00000867511, ENST00000867512, ENST00000937250, ENST00000937251, ENST00000937252, ENST00000937253, ENST00000937254, ENST00000937255, ENST00000957208, ENST00000957209, ENST00000957210, ENST00000957211

RefSeq mRNA: 5 — MANE Select: NM_032368 NM_001316973, NM_001316974, NM_001316975, NM_001316976, NM_032368

CCDS: CCDS107

Canonical transcript exons

ENST00000377223 — 8 exons

Exon	Start	End
ENSE00001065232	9935492	9935627
ENSE00001391354	9942624	9942782
ENSE00001473162	9926293	9930457
ENSE00001473225	9943249	9943391
ENSE00002963127	9934762	9934860
ENSE00003239497	9931891	9931972
ENSE00003412513	9932803	9932898
ENSE00003591741	9936519	9936627

Expression profiles

Bgee: expression breadth ubiquitous, 252 present calls, max score 94.29.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.7012 / max 162.8225, expressed in 1792 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
10257	13.0814	1789
10256	0.3906	179
10255	0.2293	61

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left testis	UBERON:0004533	94.29	gold quality
islet of Langerhans	UBERON:0000006	94.14	gold quality
right testis	UBERON:0004534	93.95	gold quality
ganglionic eminence	UBERON:0004023	93.81	gold quality
testis	UBERON:0000473	93.12	gold quality
ventricular zone	UBERON:0003053	92.47	gold quality
calcaneal tendon	UBERON:0003701	92.45	gold quality
cortical plate	UBERON:0005343	92.17	gold quality
monocyte	CL:0000576	92.07	gold quality
leukocyte	CL:0000738	91.80	gold quality
rectum	UBERON:0001052	91.67	gold quality
smooth muscle tissue	UBERON:0001135	91.44	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	90.52	gold quality
colonic epithelium	UBERON:0000397	90.49	gold quality
adrenal tissue	UBERON:0018303	90.20	gold quality
spinal cord	UBERON:0002240	89.76	gold quality
corpus callosum	UBERON:0002336	89.35	gold quality
secondary oocyte	CL:0000655	89.27	gold quality
heart left ventricle	UBERON:0002084	89.08	gold quality
tendon	UBERON:0000043	88.94	gold quality
cardiac ventricle	UBERON:0002082	88.68	gold quality
muscle of leg	UBERON:0001383	88.51	gold quality
gastrocnemius	UBERON:0001388	88.38	gold quality
pancreas	UBERON:0001264	88.35	gold quality
right atrium auricular region	UBERON:0006631	88.25	gold quality
ileal mucosa	UBERON:0000331	87.98	gold quality
heart	UBERON:0000948	87.95	gold quality
pancreatic ductal cell	CL:0002079	87.89	gold quality
mucosa of transverse colon	UBERON:0004991	87.87	gold quality
gall bladder	UBERON:0002110	87.74	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.74

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

156 targeting LZIC, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872

Literature-anchored findings (GeneRIF, showing 1)

• LZIC is functionally involved in cellular response to ionizing radiation, and its expression level could serve as a biomarker for patient stratification in clinical cancer practice. (PMID:30973299)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	lzic	ENSDARG00000055899
mus_musculus	Lzic	ENSMUSG00000028990
rattus_norvegicus	Lzic	ENSRNOG00000016200
caenorhabditis_elegans		WBGENE00022885

Paralogs (1): CTNNBIP1 (ENSG00000178585)

Protein

Protein identifiers

Protein LZIC — Q8WZA0 (reviewed: Q8WZA0)

Alternative names: Leucine zipper and CTNNBIP1 domain-containing protein, Leucine zipper and ICAT homologous domain-containing protein

All UniProt accessions (2): Q8WZA0, K7ES95

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Does not interact with CTNNB1.

Tissue specificity. Ubiquitously expressed, with highest levels in kidney. Up-regulated in several cases of gastric cancers.

Similarity. Belongs to the CTNNBIP1 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8WZA0-1	1	yes
Q8WZA0-2	2

RefSeq proteins (5): NP_001303902, NP_001303903, NP_001303904, NP_001303905, NP_115744* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR009428	ICAT_dom	Domain
IPR036911	ICAT_sf	Homologous_superfamily

Pfam: PF06384

UniProt features (4 total): chain 1, coiled-coil region 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8WZA0-F1	78.77	0.19

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 129 (showing top): RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, GOBP_RESPONSE_TO_IONIZING_RADIATION, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, COUP_01, IRF7_01, GOBP_RESPONSE_TO_RADIATION, GOBP_RESPONSE_TO_ABIOTIC_STIMULUS, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, ELK1_01, NRF2_01, BERNARD_PPAPDC1B_TARGETS_UP, CETS1P54_01, NUYTTEN_EZH2_TARGETS_DN, STAT1_02

GO Biological Process (1): response to ionizing radiation (GO:0010212)

GO Molecular Function (2): beta-catenin binding (GO:0008013), protein binding (GO:0005515)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
response to radiation	1
protein binding	1
binding	1

Protein interactions and networks

STRING

814 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LZIC	GPR157	Q5UAW9	655
LZIC	TMEM144	Q7Z5S9	557
LZIC	KTI12	Q96EK9	540
LZIC	SLC45A1	Q9Y2W3	520
LZIC	NMNAT1	Q9HAN9	516
LZIC	SLC25A33	Q9BSK2	512
LZIC	DCTPP1	Q9H773	493
LZIC	CLSTN1	O94985	479
LZIC	NAPG	Q99747	468
LZIC	KCTD9	Q7L273	462
LZIC	METTL25	Q8N6Q8	446
LZIC	PYROXD2	Q8N2H3	425
LZIC	RERE	Q9P2R6	417
LZIC	TMEM201	Q5SNT2	411
LZIC	ZDHHC16	Q969W1	405

IntAct

30 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
LZIC	ZNF558	psi-mi:“MI:0915”(physical association)	0.560
LZIC	JPH3	psi-mi:“MI:0915”(physical association)	0.560
LZIC	VCP	psi-mi:“MI:0915”(physical association)	0.560
FSD1	UBFD1	psi-mi:“MI:0914”(association)	0.530
Dctn3		psi-mi:“MI:0914”(association)	0.350
Nedd1		psi-mi:“MI:0914”(association)	0.350
PRNP	CARNS1	psi-mi:“MI:0914”(association)	0.350
LZIC		psi-mi:“MI:0914”(association)	0.350
FGB	NME2	psi-mi:“MI:0914”(association)	0.350
MBD5	NME2P1	psi-mi:“MI:0914”(association)	0.350
FGB	KIF2A	psi-mi:“MI:0914”(association)	0.350
RPL35A	SMCHD1	psi-mi:“MI:0914”(association)	0.350
METTL26	GOLGA4	psi-mi:“MI:0914”(association)	0.350
NPPB	ACOT7	psi-mi:“MI:0914”(association)	0.350
OSBPL11	DNM1L	psi-mi:“MI:0914”(association)	0.350
RAE1	NHERF1	psi-mi:“MI:0914”(association)	0.350
SCLT1	VWA8	psi-mi:“MI:2364”(proximity)	0.270
LZIC	ZNF558	psi-mi:“MI:0915”(physical association)	0.000
IKBKG	LZIC	psi-mi:“MI:0407”(direct interaction)	0.000

BioGRID (33): LZIC (Co-fractionation), LZIC (Proximity Label-MS), LZIC (Affinity Capture-MS), LZIC (Affinity Capture-MS), GINS2 (Affinity Capture-MS), CCNC (Affinity Capture-MS), CDK8 (Affinity Capture-MS), CDK19 (Affinity Capture-MS), GINS4 (Affinity Capture-MS), LZIC (Affinity Capture-MS), LZIC (Affinity Capture-MS), LZIC (Affinity Capture-MS), LZIC (Two-hybrid), LZIC (Affinity Capture-Luminescence), ZNF558 (Two-hybrid)

ESM2 similar proteins: A0A1L4BKP6, A0RHW7, A1S6A5, A4ILW6, A7GRX7, A7XXB6, A9VUB0, B7GGM5, B7H6T6, B7HMD4, B7IVI6, B7JK37, B9IW28, C1EPW3, C3LI15, C3P6V6, C7GUN6, E1SM51, O64219, O64329, P03735, P0C1D1, P10309, P23208, P25279, P27238, P27709, P28813, P76064, Q05232, Q28D79, Q2JSQ3, Q2W8K3, Q58263, Q5L118, Q5PQN7, Q5XLR1, Q5ZKW2, Q635X7, Q65K17

Diamond homologs: Q28D79, Q54ID4, Q5E9N2, Q5PQN7, Q5ZKW2, Q6DHH7, Q8K3C3, Q8WZA0, Q9JJN6, Q9NSA3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

29 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	19
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

778 predictions. Top by Δscore:

Variant	Effect	Δscore
1:9931883:GCACT:G	donor_loss	1.0000
1:9931884:CACTC:C	donor_loss	1.0000
1:9931885:ACTC:A	donor_loss	1.0000
1:9931886:CTCAC:C	donor_loss	1.0000
1:9931887:TCA:T	donor_loss	1.0000
1:9931888:C:CG	donor_loss	1.0000
1:9931889:A:AC	donor_gain	1.0000
1:9931889:ACC:A	donor_loss	1.0000
1:9931890:C:CC	donor_gain	1.0000
1:9931968:GTCAG:G	acceptor_gain	1.0000
1:9931969:TCAG:T	acceptor_gain	1.0000
1:9931970:CAG:C	acceptor_gain	1.0000
1:9931970:CAGC:C	acceptor_gain	1.0000
1:9931971:AG:A	acceptor_gain	1.0000
1:9931973:C:CC	acceptor_gain	1.0000
1:9931973:C:T	acceptor_loss	1.0000
1:9931974:T:G	acceptor_loss	1.0000
1:9935486:ACTT:A	donor_loss	1.0000
1:9935487:CTTA:C	donor_loss	1.0000
1:9935488:TTA:T	donor_loss	1.0000
1:9935489:TA:T	donor_loss	1.0000
1:9935490:A:AC	donor_gain	1.0000
1:9935491:C:CA	donor_gain	1.0000
1:9935491:CCA:C	donor_gain	1.0000
1:9935491:CCAG:C	donor_gain	1.0000
1:9935623:CCTCT:C	acceptor_gain	1.0000
1:9935624:CTCT:C	acceptor_gain	1.0000
1:9935624:CTCTC:C	acceptor_gain	1.0000
1:9935625:TCTC:T	acceptor_loss	1.0000
1:9935625:TCTCT:T	acceptor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000004707 (1:9934071 C>G,T), RS1000054293 (1:9929910 C>G), RS1000131011 (1:9942980 C>T), RS1000140613 (1:9944556 C>T), RS1000241993 (1:9922953 C>T), RS1000274119 (1:9942590 A>G,T), RS1000377735 (1:9943474 T>C), RS1000379633 (1:9938066 T>G), RS1000499493 (1:9926176 C>T), RS1000605651 (1:9932455 G>A), RS1000677210 (1:9931058 TAAAG>T), RS1000718613 (1:9924752 G>A), RS1000765081 (1:9939332 G>C), RS1001059576 (1:9932232 C>A,G,T), RS1001077962 (1:9938404 T>G)

Disease associations

OMIM: gene MIM:610458 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): breast ductal adenocarcinoma (MONDO:0005590)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST003818_38	Resting heart rate	1.000000e-07

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4296296 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol F	increases expression, affects cotreatment	2
aristolochic acid I	decreases expression	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, increases expression	1
methylparaben	decreases expression	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
torcetrapib	increases expression	1
ICG 001	increases expression	1
bisphenol B	increases expression	1
bisphenol S	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Air Pollutants	increases abundance, decreases expression	1
Atrazine	decreases expression	1
Benzo(a)pyrene	decreases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Indomethacin	increases expression, affects cotreatment	1
Ivermectin	decreases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Tretinoin	increases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
Antirheumatic Agents	increases expression	1
Copper Sulfate	decreases expression	1
Particulate Matter	increases abundance, decreases expression	1

ChEMBL screening assays

5 unique, capped per target: 5 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1243722	Binding	Binding affinity to GCN4 polypeptide L20P mutant by circular dichroism spectroscopy	Surveying polypeptide and protein domain conformation and association with FlAsH and ReAsH. — Nat Chem Biol

Clinical trials (associated diseases)

11 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00461344	PHASE2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT00637364	PHASE1/PHASE2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	PHASE1/PHASE2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	EARLY_PHASE1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	EARLY_PHASE1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01208974	Not specified	ACTIVE_NOT_RECRUITING	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery